Clinical Management of the Most Common Group A β-Hemolytic Streptococcal Infections

  • Edward L. KaplanEmail author
Part of the Current Topics in Microbiology and Immunology book series (CT MICROBIOLOGY, volume 368)


Group A streptococcal (Streptococcus pyogenes) infections remain important causes of medical and public health morbidity and mortality even during the early twenty-first century. Although most often concentrated in socially/economically disadvantaged populations, the problems remain significant in both industrializing and industrialized countries. The many M/emm types of GAS contribute to herd immunity in populations and also affect the control of streptococcal infections in these populations. Although this bacterium remains among the most susceptible to most antibiotics, it is evident that antibiotics alone have not solved the group A streptococcal medical and public health problems, even in those places where access to medical care is readily available. It is likely that the current streptococcal problems will remain difficult to manage and will remain essentially unchanged until the broad implementation of a cost-effective group A streptococcal vaccine, likely some years in the future.


Rheumatic Fever Necrotizing Fasciitis Streptococcal Infection Streptococcal Pharyngitis Scarlet Fever 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


  1. Anthony BF, Kaplan EL, Wannamaker LW, Briese FW, Chapman SS (1969) Attack rates of acute nephritis following type 49 streptococcal infection of the skin and of the respiratory tract. J Clin Invest 48:1697PubMedCrossRefGoogle Scholar
  2. Beall B, Facklam R, Thompson T (1996) Sequencing emm -specific PCR products for routine and accurate typing of group A streptococci. J Clin Microbiol 34:953–958PubMedGoogle Scholar
  3. Broderick Michael P, Hansen Christian J, Russell Kevin L, Kaplan Edward L, Blumer Jeffrey L, Faix Dennis J (2011) Serum penicillin G levels are lower than expected in adults within two weeks of administration of 1.2 million units. PLoS ONE 10:1–6Google Scholar
  4. Dajani AS, Hill PL, Wannamaker LW (1971) Experimental infection of the skin in the hamster stimulating human impetigo. II. Assessment of various therapeutic regimens. Pediatrics 48:83–90PubMedGoogle Scholar
  5. Dingle JH, Badger GF, Jordan, WS Jr (1964) Illness in the home. The Press of Western Reserve University, Cleveland, Ohio, pp 97–117Google Scholar
  6. Ferrieri P, Dajani AS, Wannamaker LW (1974) A controlled study of penicillin prophylaxis against streptococcal impetigo. J Infect Dis 129:429–438PubMedCrossRefGoogle Scholar
  7. Ferrieri P, Dajani AS, Wannamaker LW, Chapman SS (1972) Natural history of impetigo. I. Site sequence of acquisition and familial patters of spread of cutaneous streptococci. J Clin Invest 51:2851–2862PubMedCrossRefGoogle Scholar
  8. Gerber MA, Baltimore RS, Eaton CB, Gewitz M, Rowley AH, Shulman ST, Taubert KA (2009) The American Heart Association. Prevention of rheumatic fever and treatment of acute streptococcal pharyngitis. Circulation 2009(119):1541–1551CrossRefGoogle Scholar
  9. Johnson DR, Kurlan R, Leckman J, Kaplan EL (2010) The human immune response to streptococcal extracellular antigens: clinical, diagnostic, and potential pathogenetic implications. Clin Infect Dis 50:481–490PubMedCrossRefGoogle Scholar
  10. Kaplan EL (1980) The group A streptococcal upper respiratory tract carrier state: an enigma. J Pediatr 97:337PubMedCrossRefGoogle Scholar
  11. Kaplan EL, Cornaglia G (2005) Persistent macrolide resistance among group A Streptococci: the lack of accomplishment after 4 decades. Clin Infect Dis 41:609–611PubMedCrossRefGoogle Scholar
  12. Kaplan EL, Johnson DR (2001) Unexplained reduced efficacy of oral penicillin V and intramuscular benzathine penicillin G in the eradication of group A streptococci from children with acute pharyngitis. Pediatrics 108:1180–1186PubMedCrossRefGoogle Scholar
  13. Kaplan EL, Top F Jr, Dudding BA, Wannamaker LW (1971) Diagnosis of streptococcal pharyngitis: the problem of differentiating active infection from the carrier state in the symptomatic child. J Infect Dis 123:490PubMedCrossRefGoogle Scholar
  14. Kaplan EL, Gastanaduy AS, Huwe BB (1981) The role of the carrier in treatment failures following antibiotic therapy for group A streptococci in the upper respiratory tract. J Lab Clin Med 98:326PubMedGoogle Scholar
  15. Kaplan EL, Berrios X, Speth J, Siefferman T, Guzman B, Quesny F (1989) Pharmacokinetics of benzathine penicillin G: serum levels during the 28 days after intramuscular injection of 1,200,000 units. J Pediatr 115:146–150PubMedCrossRefGoogle Scholar
  16. Kaplan EL, Gooch WM III, Notario GF, Craft JC (2001) Macrolide therapy of group A streptococcal pharyngitis: ten days of macrolide therapy (clarithromycin) is more effective in streptococcal eradication than five days (azithromycin) in adults. Clin Infect Dis 32:1798–802PubMedCrossRefGoogle Scholar
  17. Kaplan EL, Chhatwal GS, Rohde M (2006) Reduced ability of penicillin to eradicate ingested group A streptococci from epithelial cells: clinical and pathogenetic implications. Clin Infect Dis 43:1398–1406PubMedCrossRefGoogle Scholar
  18. LaPenta D, Rubens C, Chi E, Cleary PP (1994) Group A streptococci efficiently invade human respiratory epithelial cells. Proc Natl Acad U S A 91:12115–12119CrossRefGoogle Scholar
  19. Macris M, Hartman N, Murray B, Klein RF, Roberts RB, Kaplan EL, Horn D, Zabriskie JB (1998) Studies of the continuing susceptibility to penicillin of group A streptococcal strains isolated over a period spanning eight decades. Pediatr Infect Dis J 17:377–381CrossRefGoogle Scholar
  20. Matthys J, DeMeyere M, van Driel ML, DeSutter A (2007) Differences among international pharyngitis guidelines: not just academic. Ann Fam Med 5:436–443PubMedCrossRefGoogle Scholar
  21. McDonald MI, Towers RJ, Andrews RM, Benger N, Currie BJ, Carapetis JR (2006) Low rates of streptococcal pharyngitis and high rates of pyoderma in Australian aboriginal communities where acute rheumatic fever is hyperendemic. Clin Infect Dis 43:683–689Google Scholar
  22. Ralph AP, Carapetis JR (2012) Group A streptococcal diseases and their global burden. Curr Top Microbiol Immunol. doi  10.1007/82_2012_280
  23. Shulman ST, Bisno AL, Clegg HW, Gerber MA, Kaplan EL, Lee G, Martin JM, Van Beneden C (2012) Clinical practice guideline for the diagnosis and management of group A streptococcal pharyngitis: 2012 update by the infectious disease society of America. Clin Infect DisGoogle Scholar
  24. Stevens DL (1992) Invasive group A streptococcus infections. Clin Inf Dis 14:2–11CrossRefGoogle Scholar
  25. Stevens DL, Bisno AL, Chambers HF, Everette ED, Dellinger P, Goldstein EJC, Gorbach SL, Hirschmann JV, Kaplan EL, Montoya JG, Wade JC (2005) Practice guidelines for the diagnosis and management of skin and soft-tissue infections. Clin Infect Dis 41:1373–1406Google Scholar
  26. Streptococcal Disease Laboratory, Francis E. Warren Air Force Base; Commission on Acute Respiratory Diseases; Armed Forces Epidemiological Board and Department of Preventive Medicine. School of Medicine. Western Reserve University. Prevention of Rheumatic Fever. U.S. Armed Forces Med. J. 1951; 2:607–613Google Scholar
  27. The Red Book (2012) Report of the Committee on Infectious Diseases The American Academy of Pediatrics. IL USA, ChicagoGoogle Scholar
  28. Wannamaker LW (1970) Differences between streptococcal infections of the throat and of the skin. New Eng J Med 282:23Google Scholar
  29. Wood HF, Feinstein AR, Taranta A, Epstein JA, Simpson R (1964) Rheumatic Fever in children and adolescents. III, Comparative effectiveness of three prophylaxis regimens in preventing streptococcal infections and rheumatic recurrences. Ann Intern Med 60(Suppl 5):31–40Google Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 2013

Authors and Affiliations

  1. 1.Department of PediatricsUniversity of Minnesota Medical SchoolMinneapolisUSA

Personalised recommendations